In this issue:
- KEYNOTE-189: patient-reported outcomes
- Chemoimmunotherapy for stage IIIA disease
- Brigatinib vs crizotinib in ALK+ disease
- 1L immunotherapy ± chemotherapy
- Osimertinib and leptomeningeal metastases
- Adjuvant chemotherapy and survival
- Prognostic value of PET parameters in SCLC
- Citrus fruit intake and lung cancer risk
- Chr15q25 genetic variant and lung disease risk
- Predicting lung cancer with an algorithm
Please login below to download this issue (PDF)